Evidence map›Paper›PMID 36975466›Full record

ReviewCurrent oncology (Toronto, Ont.)2023

Kidney Injury in Children after Hematopoietic Stem Cell Transplant.

Vinson James, Joseph Angelo, Lama Elbahlawan

Open access · goldFull text readReview
In one paragraph

Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Vinson JamesDivision of Pediatric Nephrology, Department of Pediatrics, LeBonheur Children's Hospital, Memphis, TN 38105, USA.ORCID 0000-0003-2897-925X
Joseph AngeloDivision of Pediatric Nephrology, Department of Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Houston, TX 77030, USA.
Lama ElbahlawanDivision of Critical Care Medicine, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Baylor College of Medicine · USLe Bonheur Children's Hospital · USSt. Jude Children's Research Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic cell transplant (HCT), used for treatment of many malignant and non-malignant pediatric diseases, is associated with serious complications, limiting this therapy's benefit. Acute kidney injury (AKI), seen often after HCT, can occur at different stages of the transplant process and contributes to morbidity and mortality after HCT. The etiology of AKI is often multifactorial, including kidney hypoperfusion, nephrotoxicity from immunosuppressive and antimicrobial agents, and other transplant-related complications such as transplant-associated thrombotic microangiopathy and sinusoidal obstructive syndrome. Early recognition of AKI is crucial to prevent further AKI and associated complications. Initial management includes identifying the etiology of AKI, preventing further kidney hypoperfusion, adjusting nephrotoxic medications, and preventing fluid overload. Some patients will require further support with kidney replacement therapy to manage fluid overload and AKI. Biomarkers of AKI, such as neutrophil gelatinase-associated lipocalin can aid in detecting AKI before a rise in serum creatinine, allowing earlier intervention. Long-term kidney dysfunction is also prominent in this population. Therefore, long-term follow-up and monitoring of renal function (glomerular filtration rate, microalbuminuria) is required along with management of hypertension, which can contribute to chronic kidney disease.

Indexed as

Acute Kidney InjuryHematopoietic Stem Cell TransplantationBiomarkersChildHumansKidneyRenal Replacement TherapyBiomarkerscontinuous kidney replacement therapyfluid overloadhematopoietic cell transplantkidney injuryrenal replacement therapythrombotic microangiopathy

Identifiers

PMID36975466
PMCPMC10047595
OpenAlexW4324056305

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read65
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.